Peptris Technologies, an AI-driven drug discovery company, has entered into a licensing agreement with Revio Therapeutics, a specialty pharma startup focused on repurposing medicines. Under this deal, Peptris is licensing its preclinical-stage drug candidate, PEPR124 (RT001), for further development in Duchenne muscular dystrophy (DMD). The financial details remain undisclosed, but the agreement is expected to boost Peptris’ AI-driven drug research and strengthen its presence in global biotech markets.

DMD is a rare genetic disorder that leads to progressive muscle degeneration, primarily affecting boys. With few treatment options available, the global DMD market exceeds $3 billion, highlighting a strong demand for innovative therapies. PEPR124 (RT001), developed using Peptris’ proprietary AI platform, has shown promising preclinical results. It is a repurposed, mutation-agnostic, and safe therapy, potentially benefiting not only DMD patients but also those with other muscular dystrophies.

Under the agreement, Revio Therapeutics secures commercialization rights for PEPR124 (RT001) in all markets except BRICS countries, which will remain under Peptris’ control. Revio plans to discuss its clinical development strategy with the US FDA later this year and seek orphan drug designation.

Both companies will present their preclinical findings at the Muscular Dystrophy Association (MDA) Conference in Dallas, Texas, from March 16-19, 2025.